Almac Group Receives Award from COVID-19 Therapeutics Accelerator to Produce Remdesivir

November 19, 2020
BioPharm International Editors

Almac Sciences has been granted an award by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.

Almac Sciences, a member of Almac Group, has been granted an award worth US $500,000 by the COVID-19 Therapeutics Accelerator for the development of an efficient and scalable production process for remdesivir.

According to a Nov. 17, 2020 press release, the funding will enable Almac Sciences to apply its plan to improve the overall route of synthesis to remdesivir, including application of synthetic flow methodology and biocatalysis. This plan will ultimately lower raw material usage, increase global yields, and lower the overall cost of goods for the remdesivir development process.

“We are delighted to receive funding from the Therapeutics Accelerator to apply our skills in the fight against COVID-19,” said Dr. Stefan Mix, head of Biocatalysis, Almac Sciences, in the press release. “With the skillset of our multidisciplinary teams, we are confident that our developmental approach to the manufacture of remdesivir will positively impact patients’ lives who are in urgent need, regardless of their location.”

“This project highlights Almac’s strength in technology deployment through application of both innovative flow chemistry and biocatalysis technologies to support development of processes which are economical, greener, and safer to perform,” added Prof. Tom Moody, vice-president of Technology Development and commercialization at Almac Sciences and Arran Chemical Company, in the press release.

Source: Almac Group

Related Content:

News | Industry News | COVID-19 Update